Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Transthyretin Amyloid Cardiomyopathy (ATTR CM): full-pipeline trial registry
1 of 2 indexed Transthyretin Amyloid Cardiomyopathy (ATTR CM) trials are currently recruiting.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Transthyretin Amyloid Cardiomyopathy (ATTR CM): 2 US clinical trials tracked, 1 recruiting.
Transthyretin Amyloid Cardiomyopathy (ATTR CM) is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Novo Nordisk A/S, running 2 of these trials.
Enrollment posture brief
Registry condition transthyretin-amyloid-cardiomyopathy-attr-cm
OPEN 1 | RECR 50% | LATE 1 | EARLY 1 | RANK #7188 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Transthyretin Amyloid Cardiomyopathy (ATTR CM) lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Transthyretin Amyloid Cardiomyopathy (ATTR CM) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Transthyretin Amyloid Cardiomyopathy (ATTR CM) is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Novo Nordisk A/S
NCT07207811
A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis
Novo Nordisk A/S
NCT06260709
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Transthyretin Amyloid Cardiomyopathy (ATTR CM) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Transthyretin Amyloid Cardiomyopathy (ATTR CM) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Transthyretin Amyloid Cardiomyopathy (ATTR CM) page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Transthyretin Amyloid Cardiomyopathy (ATTR CM) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Novo Nordisk A/S sponsors the most Transthyretin Amyloid Cardiomyopathy (ATTR CM) trials on record, review their full trial history before evaluating a specific study. See Novo Nordisk A/S's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Transthyretin Amyloid Cardiomyopathy (ATTR CM) condition card totals 2 registered trials; most-linked intervention NNC6019-0001; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.